ESMO E-Learning: Thoracic Oncology Highlights 2015

Learning Objectives

  • To provide a general update on new developments in the treatment of patients with local/locally advanced and recurrent/metastatic non-small cell lung cancer (NSCLC), as well as patients with malignant pleural mesothelioma
  • To provide an update on the latest clinical research findings in a type of resection in early NSCLC, adjuvant therapy in resected NSCLC, immunotherapy in second-line NSCLC treatment, the role of anti-EGFR tyrosine kinase inhibitors in unselected squamous NSCLC, treatment advances in NSCLC tumours with targetable oncogenic driver alterations, and first-line treatment for malignant pleural mesothelioma
  • To view clinically meaningful findings from a treatment perspective

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.

Title Duration Content CME Points CME Test
Thoracic Oncology Highlights 2015 32 min. 51 slides 1 Take Test
Martin Reck
Read more
Niels Reinmuth
Read more

The oncology community is currently being faced with a number of significant results from clinical trials in chest tumours, mainly in patients with non-small cell lung cancer (NSCLC) histology types. The aim of this E-Learning module is to summarise from the clinical perspective some of the most important results in NSCLC and mesothelioma presented at the main oncology events in 2015. Physicians who treat patients with thoracic tumours are faced with rapid research advances, hence the need for such a module which would present all important information together.

The module consists of three parts: the first part is focused on local/locally advanced NSCLC; the second part on recurrent/metastatic NSCLC; and the third part on malignant pleural mesothelioma.  

In the first part the authors describe the efficacy and safety of wedge resection versus segmentectomy in patients with T1aN0 NSCLC and the results from the addition of bevacizumab to adjuvant chemotherapy in early stage resected NSCLC. 

In the second part of the Module, dedicated to recurrent/metastatic NSCLC, the authors describe the results from the immunotherapy in second-line, in particular nivolumab for previously treated advanced or metastatic squamous NSCLC and in patients with advanced non-squamous NSCLC after failure of platinum-based doublet chemotherapy; pembrolizumab in patients with advanced NSCLC, and atezolizumab in second/third-line therapy for NSCLC. Furthermore, the comparison afatinib versus erlotinib as second-line therapy for patients with advanced squamous NSCLC is presented. In terms of NSCLC tumours with targetable oncogenic driver alterations, the results of studies with anti-EGFR and anti-VEGF in EGFR mutated NSCLC, third generation anti-EGFR tyrosine kinase inhibitors (TKIs), second generation of anti-ALK TKIs are discussed as well as the results of studies in BRAF mutated NSCLC. 

Finally, in the third part of the module, the authors present data from the first-line study of anti-angiogenesis in patients with pleural mesothelioma. 

The authors cover the mechanism and key pathways implicated in activity and for each of the above mentioned drugs they also provide key efficacy results and safety profiles. 

For anyone who has missed any information from lung cancer studies presented last year, this E-Learning module is the perfect and easiest way to keep up-to-date with the latest clinical highlights and treatment advances in thoracic oncology.

This E-Learning module was published in 2015 and expired in 2018.

Last update: 12 October 2016

Prof Martin Reck has reported to have received honoraria for lectures and consultancy from Hoffmann-La Roche, Lilly, Bristol-Myers Squibb, MSD, Astra Zeneca, Boehringer-Ingelheim, Pfizer and Celgene.

Dr Niels Reinmuth works as a consultant for Hoffmann-La Roche, Lilly, Boehringer-Ingelheim, TEVA, Novartis and Bristol-Myers Squibb and has received honoraria from Hoffmann-La Roche, Lilly, Novartis, Boehringer-Ingelheim, Otsuka, MSD and Bristol Myers Squibb.